Precision BioSciences (DTIL) announced that it will be issued U.S. Patent No. 12,410,418 by the U.S. Patent and Trademark Office on September 9. The composition of matter claims in this U.S. patent will encompass the PBGENE-HBV ARCUS nuclease utilized in the company’s lead in vivo gene editing program, which recognizes a highly conserved target sequence present in both HBV covalently closed circular DNA and integrated HBV DNA. This U.S. patent will have an expiration date in March 2042. The company was granted patents in Europe and Hong Kong earlier this year with similar composition of matter claims.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DTIL:
- Precision BioSciences Updates Executive Employment Agreements
- Precision BioSciences: Promising Clinical Milestones and Strategic Advancements Drive Buy Rating
- Precision BioSciences Reports Significant Quarterly Loss
- Positive Outlook for Precision BioSciences Amid Promising Clinical Trial Data and Strategic Advancements
- Promising Phase 1 Data and Strong Financial Position Justify Buy Rating for Precision BioSciences’ PBGENE-HBV